% | $
Quotes you view appear here for quick access.

Exelixis, Inc. Message Board

  • jonesdexter61 jonesdexter61 Jan 24, 2013 6:12 PM Flag

    We begin the uphill move tomorrow. Nice day coming


    Sentiment: Strong Buy

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • I agree. Cabo could become a blockbuster.
      Cabozantinib Targets Key Pathways in Cancer Progression and Metastasis
      Chemical structure of CabozantinibAs a MET and VEGFR2 inhibitor, cabo inhibits both metastasis and angiogenesis. MET is known to be up-regulated in many tumor types and is thought to facilitate metastasis. MET expression has been observed in both primary and metastatic prostate carcinomas with higher MET levels observed in bone metastases. The ligand for MET, hepatocyte growth factor (HGF) is overexpressed in prostate cancer. HGF plasma levels are a prognosis marker for prostate cancer, with increased plasma levels of HGF observed to be associated with decreased overall survival in CRPC. Both MET and HGF are up-regulated by the androgen signaling pathway in prostate cancer, according to preclinical studies. Additionally, there is evidence that both MET and VEGFR signaling pathways have a crucial role in the function of osteoblasts and osteoclasts, cells in the bone microenvironment that are often found to be dysregulated during bone metastases onset and progression.

      Sentiment: Strong Buy

15.31+0.42(+2.82%)Sep 26 4:00 PMEDT